Ibogaine Stats & Data

1930s–1966

Total synthesis of ibogaine was achieved in 1956, with its molecular structure subsequently confirmed through X-ray crystallography in 1960. Additional synthetic methodologies continued to be developed, with G. Büchi accomplishing a complete synthesis in 1966. During this period, ibogaine also maintained a commercial presence in France. From the 1930s through 1966, it was marketed as Lambarène, an extract of Tabernanthe manii promoted as a mental and physical stimulant. Each tablet contained approximately 200 mg of extract with relatively low doses of 4 to 8 mg ibogaine. The product gained popularity among post-World War II athletes before being withdrawn from the French market in 1966 when ibogaine-containing products were prohibited. Another formulation marketed during this era was Iperton, which contained Tabernanthe iboga extract at 40 mg per dose unit.

1962–1992

Anecdotal observations regarding ibogaine's potential therapeutic effects began emerging in the early 1960s. The compound's anti-addictive properties were discovered serendipitously in 1962 by Howard Lotsof, then 19 years old, when he and five friends—all heroin users—noticed subjective reductions in craving and withdrawal symptoms while taking the substance. Subsequent observations convinced Lotsof of its potential utility in treating substance dependence, leading him to contract with a Belgian company to produce ibogaine tablets for clinical trials in the Netherlands. He was awarded a United States patent for the product in 1985. Beyond addiction treatment, ibogaine was also explored in psychotherapeutic contexts during this period. Researchers documented physician-patient interactions emphasizing early memory recall and the reliving of past experiences, with notable work conducted by Claudio Naranjo. In 1992, Eric Taub established the first ibogaine treatment center at an offshore location near the United States, initiating treatments and advocating for broader recognition of the compound. He was subsequently joined in Costa Rica by Lex Kogan, another prominent figure in the field. Together, they systematized ibogaine administration protocols and established medically monitored treatment clinics across several countries. Since then, clinics have been founded worldwide to serve individuals seeking to reduce or eliminate dependence on other substances, particularly opioids.

2025–present

Interest in ibogaine as a potential treatment for addiction has continued to grow. In 2025, the state of Texas allocated $50 million to fund clinical research on ibogaine, with the stated goal of developing FDA-approved treatments for opioid use disorder, co-occurring substance use disorders, and other ibogaine-responsive conditions. The initiative, supported by former Governor Rick Perry, established a consortium of universities, hospitals, and drug developers, positioning Texas as a potential center for psychedelic medicine research.

Ibogaine has appeared in various cultural and media contexts over the decades. In 1972, gonzo journalist Hunter S. Thompson published a satirical article in Rolling Stone while covering the Democratic primary campaign, falsely asserting that candidate Edmund Muskie was addicted to ibogaine. The piece was not recognized as satire by many readers and other journalists, and the unfounded accusation reportedly damaged Muskie's reputation—Thompson later expressed surprise that anyone had believed it. The substance has also been the subject of several books. Author and Yippie activist Dana Beal co-authored "The Ibogaine Story" in 1997. Daniel Pinchbeck described his personal ibogaine experience in "Breaking Open the Head" (2002) and a subsequent Guardian article titled "Ten years of therapy in one night" (2003). More recently, musician and author Geoff Rickly based his debut novel "Someone Who Isn't Me" on his experiences with heroin addiction and treatment at an ibogaine clinic in Mexico.